Anti-Mannosidase Antibody Development Service
Mannosidases are a critical subset of the glycoside hydrolase family, responsible for cleaving terminal mannose residues from N-linked glycans. These enzymes play pivotal roles in glycoprotein maturation, lysosomal catabolism, and cellular signaling. At Creative Biolabs, we provide a comprehensive Anti-Glycan Related Enzyme Antibody Development Service tailored to the specific needs of researchers studying these complex biological pathways. Our specialized platform overcomes the structural challenges associated with mannosidase immunogens, delivering high-affinity tools for investigating lysosomal storage diseases and comparative immunology in research settings.
Understanding Mannosidases in Glycobiology
Mannosidases are classified primarily into alpha-mannosidase and beta-mannosidase based on the anomeric linkage they hydrolyze. They are essential for the orderly degradation of glycoproteins in the lysosome and the processing of N-glycans in the ER and Golgi apparatus. Deficiencies in these enzymes lead to severe metabolic disorders, most notably alpha-mannosidosis and beta-mannosidosis, which are characterized by the accumulation of undegraded mannose-rich oligosaccharides.
Beta-mannosidosis is an ultra-rare lysosomal storage disease caused by mutations in the MAN2B1 gene. Research into the pathophysiology of this condition relies heavily on the ability to detect and quantify the beta-galactosidase-like activity of mannosidases in various tissues. However, the high degree of sequence homology between different glycosyl hydrolase family members often complicates the generation of specific reagents. Furthermore, as these are carbohydrate-processing enzymes, the proteins themselves are often heavily glycosylated, creating steric hindrance that can mask critical epitopes from standard antibodies.
Structural Complexity
Mannosidases exist in multiple isoforms with distinct subcellular localizations (lysosomal, Golgi, cytosolic), making isoform-specific targeting difficult.
High Homology
Conserved catalytic domains across the glycosyl hydrolase family increase the risk of cross-reactivity with other glycan enzymes.
Low Immunogenicity
Highly conserved sequences across species often result in poor immune responses in traditional host animals, requiring specialized adjuvant strategies.
Glycosylation Interference
The heavy glycosylation of the enzyme itself can shield peptide epitopes, necessitating the use of deglycosylated immunogens or peptide mapping.
Anti-Mannosidase Antibody Development Workflow
Request a Quote
Comprehensive Solutions for Anti-Mannosidase Antibody Development
We offer a modular service designed to address the unique challenges of developing antibodies against carbohydrate-active enzymes (CAZymes). Whether you are investigating the biochemical defect in beta-mannosidosis or mapping the expression of Golgi mannosidases in cell lines, our platform provides the precision required for robust data.
Anti-Lysosomal Mannosidase Antibody Development
Targeting the acidic environments of the lysosome requires antibodies that remain stable at low pH. We develop reagents specific for lysosomal alpha-mannosidase (MAN2B1) and beta-mannosidase, validated for use in immunofluorescence colocalization studies with lysosomal markers. These tools are essential for characterizing the enzymatic void in lysosomal storage disorders.
Anti-Golgi/ER Mannosidase Antibody Development
For researchers studying N-glycan processing, we generate antibodies against Class I and Class II mannosidases (e.g., MAN1A1, MAN1A2). Our screening strategy emphasizes the differentiation between ER-resident and Golgi-resident isoforms, enabling precise subcellular fractionation and microscopy analysis of the secretory pathway.
Isoform-Specific Discrimination
Distinguishing between closely related family members is a common hurdle. We utilize peptide-based immunization strategies targeting unique loop regions within the catalytic domain. This approach ensures that the resulting antibody binds exclusively to the intended mannosidase isoform without cross-reacting with other glycosyl hydrolases or glucosidase enzymes.
Assay-Ready Validation
Beyond generation, we offer extensive validation services. We can verify antibody performance in Western Blotting to detect endogenous enzyme levels, or in immunoprecipitation (IP) assays to isolate enzyme complexes. We also support the development of sandwich ELISAs for quantitative measurements of mannosidase protein levels in biological fluids.
Why Choose Creative Biolabs?
Deep Enzymology Expertise
Our team understands the structural nuances of glycoside hydrolases, enabling smarter immunogen design.
High Specificity
Proprietary screening algorithms eliminate cross-reactivity with homologous enzymes.
Diverse Host Options
From standard mouse hybridomas to rabbit and llama models for higher affinity binding.
Data-Driven Validation
Full analytical reports including affinity kinetics, epitope mapping, and stability data.
Start Your Project
Understanding the enzymatic machinery of the cell is crucial for advancing research into metabolic diseases. Creative Biolabs is committed to providing the specialized antibodies needed to unlock these insights. Contact us today to discuss your target mannosidase and experimental requirements.
Contact Us
Published Data
The mannosidase-like protein EDEM3 is a critical component of the endoplasmic reticulum-associated degradation (ERAD) pathway, functioning primarily as a pro-survival factor within the context of prostate oncology. Comprehensive transcriptomic and functional analyses have revealed that this specific glycosyl-hydrolase is consistently upregulated in tumor tissues, where its high expression levels are significantly associated with poor patient prognosis and reduced disease-free survival. Mechanistically, EDEM3 aids in maintaining protein homeostasis under stress; its depletion triggers a robust unfolded protein response (UPR) and pro-apoptotic signaling, thereby sensitizing cancer cells to therapeutic interventions. Crucially, studies utilizing specific anti-EDEM3 antibodies have demonstrated that radiation exposure induces EDEM3 expression, which in turn confers radio-resistance to prostate cancer cells. Western Blot analysis using these antibodies effectively validated the induction of EDEM3 protein levels following radiation treatment, distinguishing the upregulation of the enzyme in surviving cell populations. These findings underscore the value of high-affinity antibodies in characterizing the roles of glycosylation enzymes in therapy resistance and validate EDEM3 as a promising target for combinatorial treatments designed to enhance radiotherapy efficacy.
Fig.1
EDEM3 depletion sensitises prostate cancer cells to ER stress and radiation, while upregulation promotes radio-resistance.1
FAQs
How do you ensure your antibody distinguishes between alpha-mannosidase and beta-mannosidase?
Specific distinction is achieved through careful immunogen design. We select peptide sequences from the unique catalytic or regulatory domains that are not conserved between the alpha and beta isoforms. We then perform counter-screening against the non-target isoform to rule out cross-reactivity.
Can you generate antibodies against cytosolic mannosidase?
Yes, we can target cytosolic mannosidases (e.g., MAN2C1). Since these enzymes lack the high-mannose glycosylation found on lysosomal variants, we can often use recombinant protein immunogens. We tailor the screening strategy to identifying clones that recognize the protein in its native cytosolic conformation.
Are your antibodies suitable for detecting mannosidase in lysosomal storage disease models?
Absolutely. Our development pipeline often focuses on MAN2B1 (beta-mannosidase) and MAN2B2. We validate candidates using Western Blotting on lysates from normal and deficient cell lines (if available or provided) to confirm the detection of the specific enzymatic defect.
Do you offer antibodies for comparative immunology in non-human species?
Yes, mannosidases are evolutionarily conserved. We can design immunogens based on the specific sequence of your target species (e.g., mouse, zebrafish, or livestock). We analyze the sequence homology to ensure the antibody will react with the ortholog in your model organism.
What is the typical timeline for a custom project?
A standard polyclonal project typically takes 3-4 months, while a monoclonal project using hybridoma technology may take 5-7 months depending on the complexity of the screening and validation phases. We provide a detailed schedule upon project initiation.
What Our Customers Say
"We needed a specific antibody for MAN2B1 to distinguish it from other lysosomal hydrolases in our knockout cell lines. The antibody Creative Biolabs produced was incredibly specific and worked perfectly in our Western Blots."
"Isolating the Golgi-resident mannosidase complex was challenging due to low abundance. The custom antibody had high affinity, allowing us to successfully immunoprecipitate the enzyme for mass spectrometry analysis."
"Excellent technical support. The team helped us design a peptide immunogen that avoided the heavily glycosylated regions of the protein. The resulting antibody recognized the native protein very well."
"We use their anti-mannosidase antibodies for comparative studies in zebrafish models. The cross-reactivity was exactly as predicted by their initial analysis. A reliable partner for custom reagents."
Reference:
- Scott, E., et al. "Pro-Survival Factor EDEM3 Confers Therapy Resistance in Prostate Cancer." International Journal of Molecular Sciences 23.15 (2022): 8184. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms23158184
Supports
- Glycosyltransferase & Glycosidase Substrate Microarray
- Glycosylation Analysis
- Custom Glycosylation of Biomolecules